scholarly journals Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status

2015 ◽  
Vol 16 (6) ◽  
pp. 2355-2359 ◽  
Author(s):  
Ilhan Hacibekiroglu ◽  
Hilmi Kodaz ◽  
Bulent Erdogan ◽  
Esma Turkmen ◽  
Asim Esenkaya ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Comparative Analysis ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Performance Status ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Efficacy And Safety ◽  
Modified Folfox6 ◽  
Gastric Cancer Patients

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

Oncology ◽  
2009 ◽  
Vol 77 (6) ◽  
pp. 349-357 ◽  
Author(s):  
Chong Kun Im ◽  
Sun Young Rha ◽  
Hei-Cheul Jeung ◽  
Jaeheon Jeong ◽  
Soo Hyeon Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Feasibility Study ◽  
Phase Ii ◽  
Performance Status ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Heavily Pretreated ◽  
Gastric Cancer Patients

Retrospective analysis for efficacy and safety of nivolumab in advanced gastric cancer patients (pts) with malignant ascites.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 392-392
Author(s):  
Akinori Sugaya ◽  
Shunsuke Ueyama ◽  
Hirosumi Suzuki ◽  
Takeshi Yamada ◽  
Yoshiyuki Yamamoto ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Performance Status ◽  
Progression Free Survival ◽  
Poor Performance ◽  
Standard Of Care ◽  
Malignant Ascites ◽  
Poor Performance Status ◽  
Efficacy And Safety ◽  
Neutrophil Lymphocyte Ratio

392 Background: Nivolumab is a standard of care as the later-line therapy for advanced gastric cancer. However, there are few data about efficacy and safety of nivolumab for pts with malignant ascites. Methods: We conducted a multicenter retrospective study for pts with advanced gastric cancer who received nivolumab alone from Oct. 2017 to Feb. 2019. Pts were divided into two groups; high ascites burden (HAB) with moderate or massive ascites and non-HAB with none or a small amount of localized ascites at pelvis and/or liver surface. Results: A total of 72 pts (23 pts with HAB and 49 pts with non-HAB) were evaluable. The HAB group had more pts with young (median 62 vs 70 years), female (35 vs 14 %), no prior gastrectomy (63 vs 35 %) and poor performance status (PS > 1; 26 vs 10 %), compared to the non-HAB group. Disease control rate was 44% (95% CI 23-64%) in the HAB group and 57% (95% CI 43-71%) in the non-HAB group. Ascites decreased in 4 pts (17%) and completely disappeared in 2 pts (8.7%) in the HAB group. These 6 pts were all male and had prior ramucirumab treatment with a mean neutrophil-lymphocyte ratio 2.1 (from 0.85 to 3.7) at the initiation of nivolumab. After 5 months of follow up period, disease progression or death events for progression-free survival (PFS) occurred in 74% of the HAB group and 53% of the non-HAB group. Median PFS was 1.0 (95%CI 0.5-1.5) and 2.6 (95%CI 0.9-7.4) months in pts with HAB and non-HAB, respectively. PFS rates at 6 months were 31% in the HAB group and 33% in the non-HAB group. Immune-related adverse events occurred in 26% of the HAB group and 16% of the non-HAB group including one and two pts with grade 3 or 4 events, respectively. There was no treatment-related death in both groups. Conclusions: Although pts with HAB showed trends of worse outcomes compared with those with non-HAB, nivolumab was suggested to provide a survival benefit to some pts with HAB, and was tolerable in the HAB group.

scholarly journals Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

2020 ◽  
Author(s):  
Toshihiko Matsumoto ◽  
Yosuke Yamamoto ◽  
Yusuke Kurioka ◽  
Ukyo Okazaki ◽  
Shogo Kimura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Advanced Gastric Cancer ◽  
Performance Status ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Efficacy And Safety ◽  
The Poor ◽  
Good Group ◽  
Poor Group

Abstract Background: Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcomes compared to best supportive care among AGC patients who received at least two prior regimens. However, there are no reliable data regarding AGC patients with poor performance status (PS) who received nivolumab. We investigated the efficacy and safety of nivolumab among AGC patients with poor PS. Methods: We retrospectively collected clinicopathologic data from patients with AGC who underwent nivolumab monotherapy at our institution from October 2017 to June 2019. Results: Forty-nine AGC patients who received nivolumab were assessed. Twenty-seven patients had PS 0 or 1 (Good group) and 22 had PS 2 or 3 (Poor group). The median progression-free survival and overall survival durations were 61 and 180 days in the Good group, respectively, and 36 and 85 days in the Poor group, respectively. The overall survival was significantly shorter in the Poor group (180 vs 85 days, p =0.0255). The disease control rates were 23% and 9% in the Good and Poor groups, respectively. Thirty-three percent of patients experienced immune-related adverse events in the Good group, and 18% in the Poor group. Conclusion: Nivolumab has a modest effect and is feasible as third- or later-line treatment for AGC patients.

scholarly journals Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Toshihiko Matsumoto ◽  
Yosuke Yamamoto ◽  
Yusuke Kuriona ◽  
Ukyo Okazaki ◽  
Shogo Kimura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Poor Performance ◽  
Efficacy And Safety ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document